[{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Benchmark Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2023","type":"Public Offering","leadProduct":"CTM-N2D","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"CytoMed Therapeutics \/ Benchmark Company","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ Benchmark Company"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2023","type":"Collaboration","leadProduct":"Gamma Delta T Cell-based Therapy","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CytoMed Therapeutics \/ MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"CytoMed Therapeutics \/ MD Anderson Cancer Center"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Sengkang General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2024","type":"Collaboration","leadProduct":"Mesenchymal Stem Cell Therapy","moa":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"","sponsorNew":"CytoMed Therapeutics \/ Sengkang General Hospital","highestDevelopmentStatusID":"2","companyTruncated":"CytoMed Therapeutics \/ Sengkang General Hospital"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CTM-N2D","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"CytoMed Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CytoMed Therapeutics","sponsor":"SunAct Cancer Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Cell and Gene therapy","year":"2025","type":"Collaboration","leadProduct":"CTM-N2D","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"CytoMed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CytoMed Therapeutics \/ SunAct Cancer Institute","highestDevelopmentStatusID":"6","companyTruncated":"CytoMed Therapeutics \/ SunAct Cancer Institute"}]